Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis

• Status: COMPLETED
• Trial end date: 2024-01-02

Summary

This study aims to evaluate the clinical and histological effects of two rituximab-based regimens in fibrillary glomerulonephritis.

• Phase: PHASE4

Details

• Lead Sponsor: University of Turin, Italy